StockData
Tonix Pharmaceuticals Holding Corp. logo

Tonix Pharmaceuticals Holding Corp. (TNXP) stock

TNXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3086% below fair value
$2.38−0.17 (-6.67%)

Close on Nov 20, 2026Market cap $40.82MP/E –Yield –

Tonix Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Tonix Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was -$158.11M. For fiscal 2025 it was -$103.21M. The highest annual figure on record is -$1.27M in fiscal 2010.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$103.21M–
FY2024Dec 31, 2024-$61.05M–
FY2023Dec 31, 2023-$109.90M–
FY2022Dec 31, 2022-$146.20M–
FY2021Dec 31, 2021-$110.86M–
FY2020Dec 31, 2020-$57.13M–
FY2019Dec 31, 2019-$26.70M–
FY2018Dec 31, 2018-$23.98M–
FY2017Dec 31, 2017-$19.13M–
FY2016Dec 31, 2016-$37.38M–
FY2015Dec 31, 2015-$42.65M–
FY2014Dec 31, 2014-$23.16M–
FY2013Dec 31, 2013-$8.53M–
FY2012Dec 31, 2012-$5.75M–
FY2011Dec 31, 2011-$2.64M–
FY2010Dec 31, 2010-$1.27M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$42.83M–
Q1 FY2026Mar 31, 2026-$44.01M–
Q4 FY2025Dec 31, 2025-$41.52M–
Q3 FY2025Sep 30, 2025-$29.74M–
Q2 FY2025Jun 30, 2025-$15.36M–
Q1 FY2025Mar 31, 2025-$16.59M–
Q4 FY2024Dec 31, 2024-$14.63M–
Q3 FY2024Sep 30, 2024-$18.81M–
Q2 FY2024Jun 30, 2024-$9.92M–
Q1 FY2024Mar 31, 2024-$17.68M–
Q4 FY2023Dec 31, 2023-$22.78M–
Q3 FY2023Sep 30, 2023-$25.20M–
Q2 FY2023Jun 30, 2023-$25.21M–
Q1 FY2023Mar 31, 2023-$36.71M–
Q4 FY2022Dec 31, 2022-$26.97M–
Q3 FY2022Sep 30, 2022-$32.36M–
Q2 FY2022Jun 30, 2022-$35.61M–
Q1 FY2022Mar 31, 2022-$51.26M–
Q4 FY2021Dec 31, 2021-$48.07M–
Q3 FY2021Sep 30, 2021-$20.70M–
Q2 FY2021Jun 30, 2021-$20.54M–
Q1 FY2021Mar 31, 2021-$21.56M–
Q4 FY2020Dec 31, 2020-$18.45M–
Q3 FY2020Sep 30, 2020-$19.30M–
Q4 FY2019Dec 31, 2019-$6.69M–
Q3 FY2019Sep 30, 2019-$6.65M–
Q2 FY2019Jun 30, 2019-$4.72M–
Q1 FY2019Mar 31, 2019-$8.65M–
Q4 FY2018Dec 31, 2018-$6.82M–
Q3 FY2018Sep 30, 2018-$4.89M–
Q2 FY2018Jun 30, 2018-$5.49M–
Q1 FY2018Mar 31, 2018-$6.77M–
Q4 FY2017Dec 31, 2017-$4.93M–
Q3 FY2017Sep 30, 2017-$5.05M–
Q4 FY2016Dec 31, 2016-$5.44M–
Q3 FY2016Sep 30, 2016-$8.39M–

More Tonix Pharmaceuticals figures

See a number that looks wrong?